Lilly files lasmiditan for migraine
Eli Lilly has filed an application in the US to market lasmiditan for the acute treatment of migraine with or without aura in adults.
Read More
Tag: lasmiditan
Lilly’s novel migraine drug hits PhIII targets
Eli Lilly’s investigational, oral, first-in-class molecule lasmiditan has hit key targets a late-stage trial assessing its safety and efficacy as a treatment for acute migraine, raising hopes for a new approach to managing the condition.
Read More
Lilly shells out $960m on CoLucid
Eli Lilly is buying US biopharma CoLucid in a deal worth around $960 million, in a move designed to boost its migraine pain management portfolio with a late-stage candidate offering a potential near-term market launch.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
